Pfizer (NYSE:PFE) Stock Price Down 1.3% - Here's Why

Key Points

• FDA approval for a Pfizer–Arvinas breast cancer therapy, a late‑stage win for Elrexfio, and an accepted PADCEV sBLA provide multiple near‑ to medium‑term oncology revenue opportunities and reduce development risk.
• Vyndamax exclusivity extended to 2031 through patent settlements, delaying generic competition and protecting a meaningful revenue stream into the next decade.
• Despite these catalysts, the stock was down 1.3% (around $26.35) as analysts remain cautious (consensus "Hold", $28.74 target) ahead of Q1 results, while Pfizer pays a 6.5% dividend but with a high 126% payout ratio.

Pfizer Inc. (NYSE:PFE - Get Free Report) traded down 1.3% on Friday . The stock traded as low as $26.29 and last traded at $26.3450. 29,200,234 shares changed hands during trading, a decline of 32% from the average session volume of 42,856,281 shares. The stock had previously closed at $26.70.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA approval for a Pfizer–Arvinas breast cancer therapy — The U.S. FDA approved the co‑developed drug for a breast cancer indication, giving Pfizer an additional commercial launch and validating its oncology partnership pipeline. This approval creates a new near‑ and medium‑term revenue opportunity and reduces development risk for the asset. US FDA approves Pfizer, Arvinas' breast cancer drug
• Positive Sentiment: Vyndamax patent settlements extend exclusivity to 2031 — Pfizer reached settlements with multiple generic filers that effectively push back generic entry for Vyndamax (tafamidis), protecting a meaningful revenue stream and reducing downside risk from near‑term generic competition. That supports cash flow visibility into the next decade. Pfizer Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031
• Positive Sentiment: Late‑stage win for multiple myeloma drug Elrexfio — Pfizer reported a late‑stage trial success for Elrexfio, which could expand its oncology franchise and add future revenue streams if regulatory filings follow. Clinical wins can meaningfully re‑rate biotech exposure over time. Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio
• Positive Sentiment: PADCEV supplemental BLA accepted for priority review — Pfizer (with Astellas) secured FDA acceptance of a PADCEV sBLA for a new use, which could expand indications and sales if approved. This is another program that supports medium‑term growth optionality. Pfizer Among Best Medical Stocks Under $30 to Invest In?
• Neutral Sentiment: Q1 earnings and guidance in focus (May 5) — Wall Street is watching first‑quarter results and guidance; Zacks and other outlets highlight consensus estimates and key revenue/margin line items, with traders positioning ahead of potential beats and for commentary on obesity and specialty drug performance. Earnings will likely be the short‑term catalyst for direction. Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
• Negative Sentiment: Analyst caution and price‑target cuts are weighing on sentiment — Goldman reportedly trimmed its target and some sell‑side commentary highlights growth concerns despite the patent wins; Morgan Stanley reiterated Equal Weight and flagged patent/growth uncertainty. That cautious analyst tone can sap momentum and contribute to intraday selling. Pfizer Stock Opinions on Vyndamax Settlements and Earnings Outlook Morgan Stanley Maintains Pfizer at Equal Weight

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. CICC Research assumed coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an "outperform" rating and a $33.00 price objective on the stock. HSBC lifted their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a "buy" rating in a research report on Tuesday, March 17th. BMO Capital Markets reissued an "outperform" rating and set a $30.00 target price on shares of Pfizer in a research note on Monday, March 9th. Zacks Research raised shares of Pfizer from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 24th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Pfizer has an average rating of "Hold" and a consensus price target of $28.74.

Pfizer Stock Down 1.3%

The business's 50 day simple moving average is $27.17 and its 200-day simple moving average is $26.09. The company has a market cap of $149.80 billion, a price-to-earnings ratio of 19.37 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company's revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the business posted $0.63 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's payout ratio is presently 126.47%.

Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently modified their holdings of the business. Y Intercept Hong Kong Ltd bought a new position in Pfizer in the 3rd quarter valued at about $3,019,000. Money Concepts Capital Corp boosted its stake in shares of Pfizer by 29.9% in the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company's stock valued at $6,325,000 after purchasing an additional 57,188 shares in the last quarter. Kepler Cheuvreux Suisse SA acquired a new stake in shares of Pfizer in the 3rd quarter valued at approximately $16,613,000. Penn Davis Mcfarland Inc. boosted its stake in shares of Pfizer by 50.9% in the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company's stock valued at $4,266,000 after purchasing an additional 57,777 shares in the last quarter. Finally, Callahan Advisors LLC boosted its stake in shares of Pfizer by 6.5% in the 3rd quarter. Callahan Advisors LLC now owns 713,797 shares of the biopharmaceutical company's stock valued at $18,188,000 after purchasing an additional 43,454 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.